Torcetrapib: Down in Flames

As you might have heard, Pfizer yanked torcetrapib out of the pipeline this weekend, just two days after the brass had hailed the new lipitor/torcetrapib hybrid as the crown jewel of the new product profile. The ramifications are unsettling to say the least. With Lipitor set to come off patent next year, there's a huge gaping hole in Pfizer's portfolio and there appear to be few projects with the legs to fill the gap in the short term. Feel free to look over the technical details.This comes on the heels of Pfizer announcing a large cut to its sales force, as well as as-yet-unannounced cuts across the entire company in January. I have a feeling it's going to be an atrocious new year for my pals over in the Ann Arbor campus